Urinary the mitochondrial dna in prognosis of the kidney diseases

Received: 03-Jan-2022, Manuscript No. PULJKTD-22-4089; Editor assigned: 05-Jan-2022, Pre QC No. PULJKTD-22-4089(PQ); Reviewed: 18-Jan-2022 QC No. PULJKTD-22-4089 (Q); Revised: 20-Jan-2022, Manuscript No. PULJKTD-22-4089(R); Published: 25-Jan-2022, DOI: 10.37532/puljktd.22.5(1).1-2

Citation: White A. Urinary mitochondrial dna in prognosis of kidney diseases. J Kidney Treat Diagn. 2022;5(1):1-2.

This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (http://creativecommons.org/licenses/by-nc/4.0/), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Introduction

Kidney infections have a long course and are hard to fix, which force a significant weight on patients and society. As per a new report; the yearly expense of Acute Kidney Injury (AKI) related hospitalization in England was assessed to be £1.02 billion, marginally higher than 1% of the National Health Service spending plan. Besides, the lifetime cost of post-release care for AKI patients conceded during 2010–11 was assessed to be £179 million. In 2017; around 700 million instances of Constant Kidney Disease (CKD) were accounted for, making it the twelfth driving reason for death; it is critical to concentrate on the pathogenesis of renal injury and foster better restorative medications for the treatment of kidney sicknesses. Mitochondrial damage plays a key role in the onset and progression of renal disease. However, the current mitochondrial function assays limit our capacity to recognize the link between mitochondrial abnormalities and kidney injury [1]. Recent results on urine mitochondrial DNA may be able to overcome these constraints (UmtDNA). Increased Urinary mitochondrial DNA levels could be used as a surrogate biomarker for mitochondrial malfunction, kidney injury, and kidney disease development and prognosis. We examine recent Urinary mitochondrial DNA research progress in renal disease detection, emphasise research topics that should be pursued in the future, and propose future prospects in this paper.

The nuclear genome, mitochondria have their own genome, called mitochondrial DNA (mtDNA), which is found in the organelle matrix and protected by a double membrane system made up of external and internal mitochondrial membranes [2]. MtDNA is a circular, intron-free, double-stranded haploid DNA strand that contains 37 genes and is 16.5 kb in size. The mtDNA of humans encodes 13 proteins, all of which are needed for oxidative phosphorylation and are components of the electron transport chain [3]. Because of a variety of factors, mtDNA is known to be more susceptible to oxidative damage than nuclear DNA. First, mtDNA is not protected by histones and is found near the mitochondrial membrane, which produces reactive oxygen species. Second, because mtDNA replication is asymmetric, the heavy strand stays single-stranded for a long time [4] making it more susceptible to spontaneous deamination. Third, mtDNA can be damaged by lower reactive oxygen species concentrations than genomic DNA, and the mtDNA damage repair mechanism is slower than genomic DNA damage under long-term oxidative stress [5].

When mitochondria are broken, their contents, including mtDNA, leak out into the extracellular space and eventually into the bloodstream. The glomeruli filter the mtDNA fragments in the systemic circulation, which are then actively released into the urine [6]. As a result, cell-free mtDNA can be discovered in blood, urine, and other bodily fluids. As a result, extracellular mtDNA levels could be used as a proxy for mitochondrial failure and sublethal tissue injury. Furthermore, using quantitative PCR, which identifies the copy number of mtDNA [7] the amount of mtDNA in body fluids may be easily determined. Furthermore, free mtDNA has been found in plasma and is being studied as a biomarker for a variety of disorders.

FUTURE ASPECTS

Current confirmations recommend that UmtDNA might fill in as a novel biomarker for both kidney harm and renal mitochondrial injury. Rather than the current biomarkers of renal debilitation, identification of UmtDNA is painless. Further, it is not difficult to gather UmtDNA for ceaseless assessment of changes related with renal capacity and renal fix processes in AKI patients. Most examinations have shown a positive relationship among’s UmtDNA and signs of kidney capacities. Nonetheless, a couple of studies didn’t show any connection, which might be ascribed to the current renal capacity markers (e.g., blood urea nitrogen and serum creatinine) that couldn’t demonstrate the early renal injury, and the limited scale clinical examinations. In this way, there is an earnest need to perform studies with more number of tests, bigger multi-focus review, and creature model based examinations to additionally decide the likely worth of UmtDNA just as to decide the typical reach and evaluating of UmtDNA level. Because UmtDNA can come from both injured renal parenchymal cells and circulating blood filtered via the kidneys, identifying UmtDNA provided primarily by the kidneys is critical for better understanding mitochondrial injury in the kidneys. As a result, measurements of circulating mtDNA levels may be able to circumvent this constraint [8].

UmtDNA could be used as a prognostic biomarker for renal prognosis in CKD patients, as well as a predictive biomarker for AKI onset and progression. The tiny sample size, on the other hand, may result in a type I statistical mistake. To confirm the prognostic value of UmtDNA, studies with a large number of patients with varied degrees of renal disease and multiple etiologies are required [9]. In conclusion, UmtDNA could be a useful biomarker for renal mitochondrial damage, AKI progression, and CKD prognosis, and it could be exploited to design mitochondrial targeted therapeutics for nephrotic patients.

Discussion

In the New Year’s, arising confirmations have shown that the renal mitochondrial brokenness assumes a significant part in the pathogenesis of kidney sicknesses, particularly AKI and CKD. Further, different quality control components, for example, mitochondrial elements, mitophagy and biogenesis, and cell reinforcement guard instruments keep up with mitochondrial homeostasis under physiological and neurotic conditions [10]. Be that as it may, loss of these quality control instruments results in mitochondrial harm and brokenness, prompting cell passing, tissue harm, and conceivably organ disappointment. The consequences of creature tests showed that the cancellation of Drp1, associated with mitochondria parting, constricts AKI, though, the erasure of Pink1 and Park2, engaged with mitophagy, and worldwide Pgc1α, associated with the guideline of mitochondrial biogenesis, exasperates AKI [11].

Besides, unnecessary responsive oxygen species creation assumes a critical part in the improvement of CKD. Customarily, the mitochondrial brokenness is distinguished dependent on the estimation of oxidative phosphorylation process in confined mitochondrial, cell, or tissue tests, in vivo [12]. For secluded mitochondria, the best technique is the estimation of mitochondrial respiratory control, i.e., an increment in respiratory rate in light of adenosine diphosphate, while, for unblemished cells, the best strategy is the same estimation of cell respiratory control, which surveys the adenosine triphosphate creation rate, the proton release rate, the coupling proficiency, the greatest breath rate, the respiratory control proportion, and the hold breath volume. The mtDNA is known to be more helpless against oxidative harms than the atomic DNA in view of different reasons [13]. To begin with, mtDNA isn’t secured by histones and is situated close the mitochondrial layer, where responsive oxygen species are created.

Second, inferable from the unbalanced replication of mtDNA, the weighty strand stays in single-abandoned state for quite a while, making it more inclined to unconstrained deamination. Third, contrasted with the genomic DNA, lower receptive oxygen species focus can make harm mtDNA, and further the fixing system of mtDNA harm is slow than genomic DNA under long haul oxidative pressure. When mitochondria are harmed, their substances, including mitochondrial DNA are delivered into the extracellular space and afterward into the foundational flow. The mtDNA sections present in the fundamental course are then separated through the glomeruli and are effectively emitted into the pee. Along these lines, without cell mtDNA is found in blood, pee, and different tissues. Henceforth, the extracellular mtDNA level might fill in as a proxy marker of mitochondrial brokenness and sub lethal tissue harm. Besides, how much mtDNA in body liquids can be effectively measured utilizing quantitative PCR, which decides the duplicate number of mtDNA. What’s sans more mtDNA has been accounted for to be recognized in plasma and investigated as a biomarker for different sicknesses.

Correlation in Umt DNA and AKI progression 

A growing body of research points to a correlation between Umt DNA and AKI. Clinical studies have recently revealed a considerable increase in Umt DNA levels in individuals with AKI as compared to those who do not have AKI. Umt DNA is also negatively correlated with estimated glomerular filtration rate (eGFR), but positively correlated with renal injury markers like serum creatine and neutrophil gelatinase-associated lipocalin [14], according to the research. As a result of these findings, higher UmtDNA levels could be employed as a marker for renal injury and impaired kidney function.

Furthermore, studies discovered that following ischemia–reperfusion, both renal cortical mtDNA copy number and renal mitochondrial gene expression levels were lowered in vivo and were inversely linked with UmtDNA levels. These findings matched those of a research conducted in vivo after sepsis, indicating that UmtDNA is a reflection of renal mitochondrial dysfunction during AKI. Tubular injury, both subfatal and lethal, is a hallmark of AKI. After an injury, the coordinated tissue repair response kicks in to help sublethal wounded cells recover, eliminate necrotic cells and debris, and rebuild an entire, polarised renal epithelium. Furthermore, complete renal repair after a minor damage can result in full functional recovery, but partial or maladaptive repair is frequently associated with severe or recurrent AKI, which can lead to nephrotic unit loss, tubulointerstitial fibrosis, and eventually CKD [15].

Because the regeneration of renal tubular epithelium is a high-energy process, mitochondrial activity is critical for the kidney’s structural and functional recovery. UmtDNA predicted AKI progression [16] according to the receiver operator characteristic curve analysis. Similarly [17] investigations have found that UmtDNA predicts the development of AKI in patients with sepsis or in surgical intensive care units. These findings have also been confirmed in AKI mice and rat models. UmtDNA levels may be a useful sign of AKI progression and a predictive indication of renal damage healing because mitochondrial disruption causes energy depletion and partial renal repair.

REFERENCES

1. Morton RL, Schlackow I, Gray A, et al. Impact of CKD on household income. Kidney Int rep. 2018;3:610-618.
   

   Google Scholar   Cross Ref

2. Eirin A, Saad A, Tang H, et al. Urinary mitochondrial DNA copy number identifies chronic renal injury in hypertensive patients. Hypertension.2016;68:401­-410.
   

   Google Scholar    Cross Ref

3. Wallace DC. Mitochondrial DNA mutations in disease and aging. Environ mol mutagen. 2010;51:440-450.
   

   Google Scholar   Cross Ref

4. Tanaka M, Ozawa T. Strand asymmetry in human mitochondrial DNA mutations. Genomics. 1994;22:327-335.
   

   Google Scholar    Cross Ref

5. Sharma P, Sampath H. Mitochondrial DNA integrity: role in health and disease. Cells. 2019;8:100.
   

   Google Scholar   Cross Ref

6. Oka T, Hikoso S, Yamaguchi O, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485:251-255.
   

   Google Scholar   Cross Ref

7. Rooney JP, Ryde IT, Sanders LH, et al. PCR based determination of mitochondrial DNA copy number in multiple species In Mitochondrial Regulation. Hum Press N Y. 2015; 23-38.
   

   Google Scholar  Cross Ref

8. Che R, Yuan Y, Huang S, et al. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physio Renal Physio. 2014;306:367-378.
   

   Google Scholar   Cross Ref

9. Tang C, Cai J, Yin XM, et al. Mitochondrial quality control in kidney injury and repair. Nat Rev Nephrol. 2021;17:299-318.
   

   Google Scholar   Cross Ref

10. Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clinica Chimica Acta. 2019;496:108-116.
    

    Google Scholar  Cross Ref

11. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochemical J. 2011;435:297-312.
    

    Google Scholar   Cross Ref

12. Hu Q, Ren J, Ren H, et al. Urinary mitochondrial DNA identifies renal dysfunction and mitochondrial damage in sepsis-induced acute kidney injury. Oxidative med cell longev. 2018.
    

    Google Scholar   Cross Ref

13. Whitaker RM, Stallons LJ, Kneff JE, et al. Urinary mitochondrial DNA is a biomarker of mitochondrial disruption and renal dysfunction in acute kidney injury. Kidney int. 2015;88:1336-1344.
    

    Google Scholar   Cross Ref

14. Ho PW, Pang WF, Luk CC, et al. Urinary mitochondrial DNA level as a biomarker of acute kidney injury severity. Kidney dis. 2017;3:78-83.
    

    Google Scholar   Cross Ref

15. Ferguson MA, Vaidya VS, Bonventre JV. Biomarkers of nephrotoxic acute kidney injury. Toxicology. 2008;245:182-193.
    

    Google Scholar  Cross Ref

16. Yu BC, Cho NJ, Park S, et al. Minor glomerular abnormalities are associated with deterioration of long-term kidney function and mitochondrial injury. J clinical med. 2020;9:33.
    

    Google Scholar  Cross Ref

17. Wei PZ, Kwan BC, Chow KM, et al. Urinary mitochondrial DNA level in non-diabetic chronic kidney diseases. Clinica Chimica Acta. 2018;484:36-39.
    

    Google Scholar    Cross Ref